JHVEPhoto
In February, I concluded that the re-rating of Amgen (NASDAQ:AMGN) looked fair, after shares fell 15% since the announcement of the acquisition of Horizon Therapeutics (HZNP). This looked fair amidst a strong share price performance beforehand, high leverage
Please subscribe to the premium service in order to get access to more actionable ideas.
The Value Investor has a Master of Science with specialization in financial markets and a decade of experience tracking companies via catalytic company events.
As the leader of the investing group Value In Corporate Events they provide members with opportunities to capitalize on IPOs, mergers & acquisitions, earnings reports and changes in corporate capital allocation. Coverage includes 10 major events a month with an eye towards finding the best opportunities. Learn more.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
